Haematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis: Recent Advances.

Autor: Mariottini A; Department of Brain Sciences, Imperial College London, London, UK.; Department of Neurosciences, Drug and Child Health, University of Florence, Florence, Italy., De Matteis E; Department of Brain Sciences, Imperial College London, London, UK.; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy., Cencioni MT; Department of Brain Sciences, Imperial College London, London, UK., Muraro PA; Department of Brain Sciences, Imperial College London, London, UK. p.muraro@imperial.ac.uk.
Jazyk: angličtina
Zdroj: Current neurology and neuroscience reports [Curr Neurol Neurosci Rep] 2023 Sep; Vol. 23 (9), pp. 507-520. Date of Electronic Publication: 2023 Aug 17.
DOI: 10.1007/s11910-023-01290-2
Abstrakt: Purpose of Review: Autologous haematopoietic stem cell transplantation (AHSCT) is increasingly considered a treatment option for patients with multiple sclerosis (MS), an autoimmune demyelinating and degenerative disease of the central nervous system (CNS). AHSCT persistently suppresses inflammation and improves the disease course in large proportions of patients with relapsing-remitting (RR) MS. Aim of this article is to review the relevant new knowledge published during the last 3 years.
Recent Findings: Laboratory studies reported confirmatory and new insights into the immunological and biomarker effects of AHSCT. Retrospective clinical studies confirmed excellent outcomes in RRMS, showing possible superior effectiveness over standard therapies and suggesting a possible benefit in early secondary progressive (SP) MS with inflammatory features. New data on risks of infertility and secondary autoimmunity were also reported. Further evidence on the high effectiveness and acceptable safety of AHSCT strengthens its position as a clinical option for aggressive RRMS. Further research is needed to better define its role in treatment-naïve and progressive forms of MS, ideally within randomised clinical trials (RCTs).
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: